fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Lactulose

7 general benefit · 1 not a benefit

Jamp-Lactulose · DIN 02295881 · 667 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp-Lactulose · DIN 02295881 Manufacturer: Jamp Pharma Corporation; listing date 2012-09-28 Health Canada: Marketed since 2008-08-21 · brand JAMP-LACTULOSE · ATC A06AD11 LACTULOSE · form Solution · route Oral · ingredients LACTULOSE 667 MG/ML · company Jamp pharma corporation · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Lactulose: Formulary list price $0.01 per unit (the source does not state the unit; exact figure $0.0145). What the ministry pays, not the patient.

Ministry pays: $0.0145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02295881)

Source record
DIN 02295881: Jamp-Lactulose Raw flags: sec3=Y Item: 564000004; group id 679; item number 1695; lccId None; manufacturer id JPC Source form: O/L; strength: 667mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0145; ministry $0.0145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295881 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78124
Interchangeable products
Apo-Lactulose Solution · DIN 02242814 · $0.0145 Cephulac · DIN 02091925 · not recorded Lactulose · DIN 02412268 · $0.0145 PMS-Lactulose-Pharma · DIN 02469391 · $0.0145 Pharma-Lactulose · DIN 02247383 · $0.0145 Ratio-Lactulose · DIN 00854409 · $0.0145
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295881
Shortage record checked October 6, 2026

Lactulose · DIN 02412268 · 667 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Lactulose · DIN 02412268 Manufacturer: Sanis Health Inc.; listing date 2023-06-30 Health Canada: Marketed since 2023-06-19 · brand LACTULOSE · ATC A06AD11 LACTULOSE · form Solution · route Oral · ingredients LACTULOSE 667 MG/ML · company Sanis health inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Lactulose: Formulary list price $0.01 per unit (the source does not state the unit; exact figure $0.0145). What the ministry pays, not the patient.

Ministry pays: $0.0145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02412268)

Source record
DIN 02412268: Lactulose Raw flags: sec3=Y Item: 564000004; group id 679; item number 1695; lccId None; manufacturer id SAI Source form: O/L; strength: 667mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0145; ministry $0.0145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02412268 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89682
Interchangeable products
Apo-Lactulose Solution · DIN 02242814 · $0.0145 Cephulac · DIN 02091925 · not recorded Jamp-Lactulose · DIN 02295881 · $0.0145 PMS-Lactulose-Pharma · DIN 02469391 · $0.0145 Pharma-Lactulose · DIN 02247383 · $0.0145 Ratio-Lactulose · DIN 00854409 · $0.0145
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02412268
Shortage record checked October 6, 2026

PMS-Lactulose-Pharma · DIN 02469391 · 667 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Lactulose-Pharma · DIN 02469391 Manufacturer: Pharmascience Inc.; listing date 2019-01-31 Health Canada: Marketed since 2018-04-02 · brand PMS-LACTULOSE-PHARMA · ATC A06AD11 LACTULOSE · form Solution · route Oral · ingredients LACTULOSE 667 MG/ML · company Pharmascience inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Lactulose-Pharma: Formulary list price $0.01 per unit (the source does not state the unit; exact figure $0.0145). What the ministry pays, not the patient.

Ministry pays: $0.0145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02469391)

Source record
DIN 02469391: PMS-Lactulose-Pharma Raw flags: sec3=Y Item: 564000004; group id 679; item number 1695; lccId None; manufacturer id PMS Source form: O/L; strength: 667mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0145; ministry $0.0145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02469391 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95818
Interchangeable products
Apo-Lactulose Solution · DIN 02242814 · $0.0145 Cephulac · DIN 02091925 · not recorded Jamp-Lactulose · DIN 02295881 · $0.0145 Lactulose · DIN 02412268 · $0.0145 Pharma-Lactulose · DIN 02247383 · $0.0145 Ratio-Lactulose · DIN 00854409 · $0.0145
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02469391
Shortage record checked October 6, 2026

Ratio-Lactulose · DIN 00854409 · 667 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ratio-Lactulose · DIN 00854409 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2013-07-11 · brand RATIO-LACTULOSE · ATC A06AD11 LACTULOSE · form Solution · route Oral · ingredients LACTULOSE 667 MG/ML · company Teva canada limited · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Lactulose: Formulary list price $0.01 per unit (the source does not state the unit; exact figure $0.0145). What the ministry pays, not the patient.

Ministry pays: $0.0145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00854409)

Source record
DIN 00854409: Ratio-Lactulose Raw flags: sec3=Y Item: 564000004; group id 679; item number 1695; lccId None; manufacturer id RPH Source form: O/L; strength: 667mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0145; ministry $0.0145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00854409 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12699
Interchangeable products
Apo-Lactulose Solution · DIN 02242814 · $0.0145 Cephulac · DIN 02091925 · not recorded Jamp-Lactulose · DIN 02295881 · $0.0145 Lactulose · DIN 02412268 · $0.0145 PMS-Lactulose-Pharma · DIN 02469391 · $0.0145 Pharma-Lactulose · DIN 02247383 · $0.0145
Shortage status: resolved shortage (ended July 19, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00854409
Shortage record checked October 6, 2026

PMS-Lactulose · DIN 00703486 · 667 mg/mL · oral liquid

General benefitDormant since August 1, 2025 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
PMS-Lactulose · DIN 00703486 Manufacturer: Pharmascience Inc.; listing date 1996-10-01 Health Canada: Dormant since 2025-08-01 · brand PMS-LACTULOSE SYR 667MG/ML · ATC A06AD11 LACTULOSE · form Solution · route Oral · ingredients LACTULOSE 667 MG/ML · company Pharmascience inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Lactulose: Formulary list price $0.01 per unit (the source does not state the unit; exact figure $0.0147). What the ministry pays, not the patient.

Ministry pays: $0.0147 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00703486)

Source record
DIN 00703486: PMS-Lactulose Raw flags: sec3=Y Item: 561200047; group id 651; item number 1633; lccId None; manufacturer id PMS Source form: O/L; strength: 667mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0147; ministry $0.0147 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00703486 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=38260
Shortage status: discontinued (November 15, 2021, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00703486
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 1, 2025 — choose a marketed DIN from the same-category list.

Pharma-Lactulose · DIN 02247383 · 667 mg/mL · oral liquid

General benefitDormant since July 31, 2026 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Pharma-Lactulose · DIN 02247383 Manufacturer: Pharmascience Inc.; listing date 2013-06-27 Health Canada: Dormant since 2026-07-31 · brand PHARMA-LACTULOSE · ATC A06AD11 LACTULOSE · form Solution · route Oral · ingredients LACTULOSE 667 MG/ML · company Pharmascience inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Pharma-Lactulose: Formulary list price $0.01 per unit (the source does not state the unit; exact figure $0.0145). What the ministry pays, not the patient.

Ministry pays: $0.0145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247383)

Source record
DIN 02247383: Pharma-Lactulose Raw flags: sec3=Y Item: 564000004; group id 679; item number 1695; lccId None; manufacturer id PMS Source form: O/L; strength: 667mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0145; ministry $0.0145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247383 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71628
Interchangeable products
Apo-Lactulose Solution · DIN 02242814 · $0.0145 Cephulac · DIN 02091925 · not recorded Jamp-Lactulose · DIN 02295881 · $0.0145 Lactulose · DIN 02412268 · $0.0145 PMS-Lactulose-Pharma · DIN 02469391 · $0.0145 Ratio-Lactulose · DIN 00854409 · $0.0145
Shortage status: resolved shortage (ended May 7, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247383
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2026 — choose a marketed DIN from the same-category list.

Apo-Lactulose Solution · DIN 02242814 · 667 mg/mL · oral liquid

General benefit; Health Canada lists this DIN as Cancelled (unreturned annual) since 2025-01-29 — choose a marketed DIN from the same-category list.Discontinued January 29, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled (unreturned annual) since 2025-01-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled (unreturned annual) since 2025-01-29 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Lactulose Solution · DIN 02242814 Manufacturer: Apotex Inc.; listing date 2005-03-31 Health Canada: Cancelled (unreturned annual) since 2025-01-29 · brand LACTULOSE SOLUTION USP · ATC A06AD11 LACTULOSE · form Solution · route Oral · ingredients LACTULOSE 667 MG/ML · company Bajaj medical, llc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Lactulose Solution: Formulary list price $0.01 per unit (the source does not state the unit; exact figure $0.0145). What the ministry pays, not the patient.

Ministry pays: $0.0145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242814)

Source record
DIN 02242814: Apo-Lactulose Solution Raw flags: sec3=Y Item: 564000004; group id 679; item number 1695; lccId None; manufacturer id APX Source form: O/L; strength: 667mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0145; ministry $0.0145 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242814 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66642
Interchangeable products
Cephulac · DIN 02091925 · not recorded Jamp-Lactulose · DIN 02295881 · $0.0145 Lactulose · DIN 02412268 · $0.0145 PMS-Lactulose-Pharma · DIN 02469391 · $0.0145 Pharma-Lactulose · DIN 02247383 · $0.0145 Ratio-Lactulose · DIN 00854409 · $0.0145
Shortage status: discontinued (September 14, 2018, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242814
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled (unreturned annual) since January 29, 2025 — choose a marketed DIN from the same-category list.

Cephulac · DIN 02091925 · 667 mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-08-12 — choose a marketed DIN from the same-category list.Discontinued August 12, 1998 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1998-08-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1998-08-12 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Cephulac · DIN 02091925 Manufacturer: Marion Merrell Dow Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 1998-08-12 · brand CEPHULAC SYR 667MG/ML · ATC A06AD11 LACTULOSE · form Syrup · route Oral · ingredients LACTULOSE 667 MG/ML · company Hoechst marion roussel canada inc. · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Cephulac: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02091925)

Source record
DIN 02091925: Cephulac Raw flags: notABenefit=Y, sec3=Y Item: 564000004; group id 679; item number 1695; lccId None; manufacturer id MRR Source form: O/L; strength: 667mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02091925 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17103
Interchangeable products
Apo-Lactulose Solution · DIN 02242814 · $0.0145 Jamp-Lactulose · DIN 02295881 · $0.0145 Lactulose · DIN 02412268 · $0.0145 PMS-Lactulose-Pharma · DIN 02469391 · $0.0145 Pharma-Lactulose · DIN 02247383 · $0.0145 Ratio-Lactulose · DIN 00854409 · $0.0145
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02091925
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 12, 1998 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (A06A): coverage varies; not interchangeable

  • Bisacodyl (Dulcolax): general benefit
  • Docusate dioctyl sulfosuccinate (Docusate Sodium): general benefit
  • Citrus fibre + grain (Novo-Fibre): general benefit, not a benefit
  • Citric acid + oxide + picosulfate (Pico-Salax): general benefit
  • Mineral oil (Fleet Enema Mineral Oil): general benefit
  • Prucalopride (Resotran): not a benefit
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (56:12 Cathartics) and how they are covered

Matched class: 56:12 Cathartics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BISACODYL, DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE), MAGNESIUM OXIDE & CITRIC ACID & SODIUM PICOSULFATE, MINERAL OIL, PSYLLIUM MUCILLOID, SENNOSIDES A & B, SODIUM BIPHOSPHATE & SODIUM PHOSPHATE Some products covered without a code (check the product listing): GRAIN & CITRUS FIBRE 56:12 Cathartics

BISACODYL

· 5 products · General benefit · strengths: 5mg, 10mg · Ent Tab, Sup

DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)

· 6 products · General benefit · strengths: 100mg, 4mg/mL, 10mg/mL · Cap, O/L

GRAIN & CITRUS FIBRE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: · Tab

MAGNESIUM OXIDE & CITRIC ACID & SODIUM PICOSULFATE

· 2 products · General benefit · strengths: 3.5g & 12g & 10mg · Pd for Sol-12g Sachet

MINERAL OIL

· 1 products · General benefit · strengths: 100% · Enema

PSYLLIUM MUCILLOID

· 1 products · General benefit · strengths: · Oral Pd

SENNOSIDES A & B

· 2 products · General benefit · strengths: 8.6mg · Tab

SODIUM BIPHOSPHATE & SODIUM PHOSPHATE

· 2 products · General benefit · strengths: 160mg & 60mg/mL · Ped Rect Sol, Rect Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:12
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:16 Digestants, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs

Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

PRUCALOPRIDE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg · Tab

5-AMINOSALICYLIC ACID

· 17 products · General benefit (16), Listed, not a benefit (1) · strengths: 1g/Actuation, 500mg, 1.2g, 1g, 1g/100mL, 4g/100mL, 4g, 1000mg, 400mg · 14 Actuation-Foam Enema Canister Pk, Del-Release Tab, Delayed & ER Tab, DR Tab, Enema, Ent Tab, ER Tab, Rect Susp-Pk, Sup, Tab

BUDESONIDE

· 1 products · General benefit · strengths: 2mg/Act · Rectal Foam-14 Act Canister

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

DOMPERIDONE MALEATE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 10mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

MESALAZINE

· 2 products · General benefit · strengths: 800mg, 1600mg · DR Tab

METOCLOPRAMIDE HCL

· 8 products · Limited Use, codes 481, 657 (2), Listed, not a benefit (2), General benefit (4) · strengths: 5mg/mL, 5mg, 10mg · Inj Sol (Preservative Free), Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

OLSALAZINE SODIUM

· 1 products · General benefit · strengths: 250mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no link

Availability

PMS-Lactulose · DIN 00703486 Shortage status: discontinued (2021-11-15, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00703486

Check this DIN again

Apo-Lactulose Solution · DIN 02242814 Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242814

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Cephulac: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026